Cambridge, MA 02142
Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body.
Neutrolis’ lead program targets Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the innate immune system and play an important role in chronic and acute diseases.
Based in Cambridge, MA, Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and is supported by seasoned business leaders. The company’s pipeline includes NTR-441 and NTR-452 that effectively removes NETs and halt their pathologic effects.
Dr. Fox is an immunologist trained at Max Planck Institute and Harvard Medical School. Before co-founding and transitioning into Neutrolis, Toby was a Principal Investigator at University Medical Center Hamburg-Eppendorf. Toby is one of the most cited researchers in the field of NETs with important contributions characterizing the formation and clearance of NETs as well as their implications in vascular diseases and organ injuries.
Dr. Hakkim is an immunologist trained at Max Planck Institute and Harvard Medical School. Abdul’s PhD thesis was the first to report on the biology and implications of NETs in autoimmunity. At Harvard, Abdul worked on genetics of innate immunity and co-founded Genma/Artus, a spin-off out of Harvard and now Neutrolis.
DNA is a very long chain of nucleic acids that is wound around histone proteins to form chromatin, which is then packed into the nucleus of eukaryotic cells. Normally, DNA encodes proteins and the instructions needed to make cells function, but it has an additional function within our immune system. Neutrophils, the most abundant immune cells in the body, can expel their long chromatin fibers to form neutrophils extracellular traps (NETs), which activate multiple immune pathways that are implicated in many autoimmune and inflammatory diseases.
The balance between NETs formation and clearance is pivotal for maintaining homeostasis. As a result of persistent inflammation, NETs formation overwhelms the natural clearance mechanisms leading to an accumulation of NETs that exacerbates systemic immune response and end-organ damage. To date, NETs treatment strategies have predominantly focused on inhibiting the creation of NETs, a mechanism, which is conserved and highly biologically redundant.
March 9, 2018
March 9, 2017
March 9 2011
March 9, 2010
February 9, 2010
March 9 2007
*Note: Dr. Toby Fox publishes under his birth name Tobias Fuchs
Lupus is a systemic autoimmune disease that is characterized by autoantibodies against DNA and inflammation in the joints, skin, kidneys, brain, heart and lungs.
Acute respiratory distress syndrome (ARDS) occurs when the lungs are severely injured, often by infection or trauma, which causes fluid to leak into the lungs, making it difficult to get oxygen into the bloodstream.
Neutrolis is developing therapies for additional undisclosed neutrophil-driven conditions.
Cambridge, MA 02142